- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05113589
Fibromyalgia and Circadian Blood Pressure
Circadian Variation of Blood Pressure in Patients With Fibromyalgia After a Whole Body Photobiomodulation Treatment: a Triple-blinded Randomized Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Studying variations of blood pressure is a way of assessing the master circadian clock, through the diurnal/nocturnal BP ratio.
When alteration of the circadian rhythm appears, neurohumoral factors that affect autonomic nervous and cardiovascular systems are affected, which presents persistent changes in the blood pressure pattern. These alterations caused by a disturbed circadian rhythm could contribute to the pathogenesis of chronic disorders in general and especially to fibromyalgia syndrome.
The aim of the study is to analyze changes in blood pressure and central sensitisation (pain pressure threshold) after a whole-body photobiomodulation treatment in patients suffering from fibromyalgia syndrome, as well as in pain, quality of life and autonomic symptoms. Furthermore, to study the level of association between blood pressure changes and pain perception, quality of life and autonomic symptoms after the end of the treatment. Finally, to study the effects of the treatment 3 months after the end of the treatment.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Málaga, Spain
- Ana González Muñon
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients diagnosed from FM presenting generalized pain in at least four or five regions.
- Present symptoms for at least 3 months at similar levels.
Exclusion Criteria:
- Inflammatory, neurological, or orthopedic disease which can alter balance, hearing, and vision, and cognitive impairment in terms of the ability to answer questions.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PBM TREATMENT
REAL PBM TREATMENT
|
Participants randomized to this treatment will receive a whole body PBM treatment using a NovoTHOR® whole body light bed.
For each treatment session, participants will lie supine in the treatment bed for 20 minutes, with no or minimal attire (underwear).
Treatment sessions will be three times weekly for a period of 4 weeks, totalling 12 treatment sessions
|
Placebo Comparator: PLACEBO PBM
PLACEBO PBM TREATMENT
|
The placebo feature of the whole body PBM bed provides controls that select active or placebo (sham) treatments in a way undetectable by participant, operator or observers, such that no-one is aware whether the participant is receiving an active or placebo treatment.
There is a switch box that randomises participants to active or placebo; no other randomisation is necessary.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of Diurnal/nocturnal blood pressure ratio perceived at three months
Time Frame: time (t) 1(prior to treatment), t2 (immediately after treatment ), t3 (3 months after completion of treatment)
|
The diurnal/nocturnal blood pressure ratio is defined as the nocturnal decline in BP relative to the diurnal blood pressure mean, and it is calculated as 100×(mean diurnal blood pressure-mean nocturnal blood pressure)/mean diurnal blood pressure. Mean blood pressure is calculated by mean blood pressure = diastolic pressure + 1/3 (systolic pressure - diastolic pressure). There are four possible groups: extreme-dippers (diurnal/nocturnal BP ratio ≥20%), normal dippers (ratio ≥10%), non-dippers (ratio <10%), and inverse-dippers or risers (ratio <0%, indicating nocturnal BP above the diurnal mean). |
time (t) 1(prior to treatment), t2 (immediately after treatment ), t3 (3 months after completion of treatment)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline perceived pain at 3 months
Time Frame: time (t) 1(prior to treatment), t2 (immediately after treatment ), t3 (3 months after completion of treatment)
|
Visual Analogue Scale (VAS) is used by the patient to quantify the pain from 0 (without any pain) to 10 (the worst pain)
|
time (t) 1(prior to treatment), t2 (immediately after treatment ), t3 (3 months after completion of treatment)
|
Change from autonomic nervous system activity at 3 months
Time Frame: time (t) 1(prior to treatment), t2 (immediately after treatment ), t3 (3 months after completion of treatment)
|
The Autonomic Symptom Profile (ASP) is a validated self-report questionnaire that comprehensively assesses autonomic symptoms across 11 subscales and yields a composite autonomic symptom score, where higher scores mean a better outcome and lower scores mean a worst outcome.
Autonomic nervous system activity provides quantitative information regarding cardiac autonomic tone.
|
time (t) 1(prior to treatment), t2 (immediately after treatment ), t3 (3 months after completion of treatment)
|
Change from baseline Pain pressure threshold at 3 months
Time Frame: time (t) 1(prior to treatment), t2 (immediately after treatment ), t3 (3 months after completion of treatment)
|
Tender points will be assessed using a standard pressure algometer (FPK 20; Wagner Instruments, Greenwich, CT, USA.): occiput at the suboccipital muscle insertions, low cervical at the anterior aspects of the intertransverse spaces at C5-C7, trapezius at the midpoint of the upper border, supraspinatus at origins, above the scapula spine near the medial border, paraspinous 3 cm lateral to the midline at the level of the mid-scapula, second rib at the second costochondral junctions, just lateral to the junctions on the upper surfaces, lateral pectoral at the level of the fourth rib at the anterior axillary line, lateral epicondylee 2 cm distal to the epicondyles and medial epicondyle at the epicondyles.
|
time (t) 1(prior to treatment), t2 (immediately after treatment ), t3 (3 months after completion of treatment)
|
Change from elastography at 3 months
Time Frame: time (t) 1(prior to treatment), t2 (immediately after treatment ), t3 (3 months after completion of treatment)
|
Quantified elastography in tender points.
Changes in the status of myofascial trigger-points can be demonstrated with an objective and reproducible USE measure
|
time (t) 1(prior to treatment), t2 (immediately after treatment ), t3 (3 months after completion of treatment)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: SANTIAGO NAVARRO-LEDESMA, PhD, Universidad de Granada
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FMCBP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Blood Pressure
-
DongGuk UniversityActive, not recruitingHypertension | Blood Pressure | Ambulatory Blood Pressure | Home Blood Pressure MeasurementKorea, Republic of
-
SE HealthCentre for Aging and Brain Health InnovationCompletedHypertension | Blood Pressure | Hypotension | High Blood Pressure | Low Blood PressureCanada
-
ROX Medical, Inc.CompletedHypertension | Blood Pressure, High | Blood Pressure, Resistant | Blood Pressure, UncontrolledUnited Kingdom, Netherlands, Belgium
-
University of JordanCompletedBlood Pressure | Heart Rate | Airway PressureJordan
-
Istituto Auxologico ItalianoRecruitingArterial Hypertension | Ambulatory Blood Pressure Monitoring | Blood Pressure Determination | Home Blood Pressure MonitoringItaly
-
RadiRad Co., Ltd.Hualien Tzu Chi General HospitalNot yet recruitingBlood Pressure
-
Riphah International UniversityRecruiting
-
GE HealthcareNot yet recruiting
-
Guangdong Provincial People's HospitalRecruiting
-
Guangdong Provincial People's HospitalRecruiting
Clinical Trials on PBM TREATMENT
-
LumiThera, Inc.CompletedDry Age-related Macular DegenerationUnited Kingdom, Spain, France, Germany, Italy
-
LumiThera, Inc.Active, not recruitingDry Age-related Macular DegenerationUnited States
-
Biolux Research Holdings, Inc.CompletedMalocclusionUnited States, Canada, Thailand
-
University of MalagaCompletedChronic Pain | FibromyalgiaSpain
-
The University of Texas Health Science Center,...CompletedPostoperative PainUnited States
-
University of FloridaNational Institute on Aging (NIA); University of ArizonaRecruitingCognitive Aging | Alzheimer Disease, Protection AgainstUnited States
-
Seaborough Life Science B.V.University of Groningen; Chrono@Work B.V.Not yet recruitingSleep Deprivation | Circadian Rhythm Disorders
-
Universidade Federal de Sao CarlosFundação de Amparo à Pesquisa do Estado de São PauloCompleted
-
University of Nove de JulhoUnknownPhysical Therapy Modalities
-
PBM Healing International LimitedRecruitingMalocclusion | Orthodontic TreatmentCanada